Stephen Hoge, M.D., is a distinguished medical professional and executive who currently serves as the President of Moderna, Inc. Dr. Hoge joined Moderna in 2012 and has played a pivotal role in the company's growth and development. With a strong background in medicine and biotechnology, he has been instrumental in leading Moderna's efforts to develop innovative mRNA-based therapeutics and vaccines. Prior to his role at Moderna, Dr. Hoge held various positions at leading healthcare institutions, including Massachusetts General Hospital and the Broad Institute of MIT and Harvard. As President of Moderna, Dr. Hoge oversees the company's day-to-day operations and strategic initiatives. He has been a key figure in the development and commercialization of Moderna's groundbreaking COVID-19 vaccine, which has been administered to millions of people worldwide. Under his leadership, Moderna has expanded its pipeline of mRNA-based therapies targeting a wide range of diseases, including infectious diseases, cancer, and rare genetic disorders. Dr. Hoge's expertise in translational medicine and his ability to navigate complex regulatory environments have been crucial to Moderna's success in bringing novel treatments to patients. Dr. Hoge's achievements extend beyond his role at Moderna. He is a recognized thought leader in the field of mRNA technology and has published numerous scientific papers on the subject. He is also an advocate for improving access to healthcare and has been involved in initiatives aimed at addressing global health challenges. With his extensive experience, visionary leadership, and commitment to innovation, Dr. Stephen Hoge continues to drive Moderna's mission to transform the future of medicine through mRNA-based therapies.